mds: treating high and low-risk disease
Published 5 years ago • 416 plays • Length 3:15Download video MP4
Download video MP3
Similar videos
-
1:02
update on treatments for high- and low-risk mds
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
3:38
a new set of treatment options for low-risk mds
-
2:12
improving the treatment of low-risk mds: luspatercept, treatment sequencing & disease classification
-
3:08
the treatment protocol for higher risk mds
-
1:16
state of the art: mds
-
0:59
the current challenges facing high-risk mds treatment
-
1:34
perspectives on the management of low and high-risk mds
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
2:07
emerging targeted treatments for mds
-
1:34
managing adverse events with novel therapies in lower-risk mds
-
10:18
classification of high-risk mutations in mds
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:41
novel therapies for high-risk mds
-
2:11
new therapeutic options for low-risk mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:18
the importance risk stratification to enable risk-adapted therapy in mds & cmml
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
3:31
promising treatment options emerging for higher-risk mds & the value of clinical trials